In this report, the Asia-Pacific Antidote market is valued at USD XX million in 2019 and is expected to reach USD XX million by the end of 2025, growing at a CAGR of XX% between 2019 and 2025.
Antidotes are chelating drugs that are used to neutralize the effect of poison or other drugs. Antidotes are widely used to neutralized cyanide poisoning, benzodiazepine poisoning, opioid poisoning, and other toxins. Pralidoxime, naloxone, flumazenil, and dimercaprol are some of the antidotes. Antidotes are also used to neutralize the poison caused by snakebite and poison caused by a chronic medical condition.
Growing cases of snakebite across the Asia Pacific region is predominantly fueling the market growth of the antidotes. Rising prevalence of various medical conditions associated with antidotes such as trichotillomania, smoking cessation, toxoplasmosis prophylaxis, and a reversal of sedation is also contributing to the market growth. Moreover, development in the infrastructure of the healthcare industry coupled with the increasing studies by manufacturer and researcher to study the effect of antidotes in order to develop novel antidotes is further expected to accelerate the market growth. According to the Charlton Media Group, Asia's overall healthcare spending is projected to surge to US$2.27t by 2026 from US$1.69t in 2017.
Moreover, growth in the pharmaceutical industry in the Asia Pacific region is also projected to foster the market growth of the antidotes. According to the India Brand Equity Foundation, the Indian pharmaceutical sector is projected to grow to US$ 100 billion, and the medical device market expected to grow US$ 25 billion by 2025. Moreover, pharmaceutical exports from India stood at US$ 19.14 billion in 2019 and US$ 13.69 billion in 2020. Furthermore, rise in the geriatric population coupled with the increasing cases of chronic disease in the region is further expected to propel the market growth of the antidotes. According to The United Nations Population Fund By 2050, one in four people in Asia and the Pacific will be over 60 years old. The population of older persons (aged over 60) in the region will triple between 2010 and 2050, reaching close to 1.3 billion people.
On the other hand, the high cost of anti-venoms is projected to restrict the market growth of the Asia Pacific antidotes.
Key Developments:
In March 2020, Mumbai based API major, Lasa Supergenerics Ltd in partnership with the Institute of Chemical Technology (ICT) announced the commencement for the development of antiviral compound Favipiravir as Covid19 treatment. Favipiravir is an antiviral drug and is a promising antidote for the treatment of Coronavirus disease.
Geographically, this report split Asia-Pacific into several key Regions, with sales (K Units), revenue (Million USD), market share and growth rate of Antidote for these regions, from 2018 to 2025 (forecast), including
China
Japan
South Korea
Taiwan
India
Southeast Asia
Australia
Asia-Pacific Antidote market competition by top manufacturers/players, with Antidote sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including
Boehringer Ingelheim
AstraZeneca
Novartis
Eli Lilly
Portola
Pfizer
Bristol-Myers Squibb
Bayer
On the basis of product, this report displays the sales volume (K Units), revenue (Million USD), product price (USD/Unit), market share and growth rate of each type, primarily split into
Chemical Antidotes
Physical Antidotes
Pharmacological Antidotes
On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume (K Units), market share and growth rate of Antidote for each application, including
Animal Bites
Heavy Metal Poisoning
Others
If you have any special requirements, please let us know and we will offer you the report as you want.
Table of Contents
Asia-Pacific Antidote Market Report 2019
1 Antidote Overview
1.1 Product Overview and Scope of Antidote
1.2 Classification of Antidote by Product Category
1.2.1 Asia-Pacific Antidote Market Size (Sales) Comparison by Types (2014-2024)
1.2.2 Asia-Pacific Antidote Market Size (Sales) Market Share by Type (Product Category) in 2016
1.2.3 Chemical Antidotes
1.2.4 Physical Antidotes
1.2.5 Pharmacological Antidotes
1.3 Asia-Pacific Antidote Market by Application/End Users
1.3.1 Asia-Pacific Antidote Sales (Volume) and Market Share Comparison by Applications (2014-2024)
1.3.2 Animal Bites
1.3.3 Heavy Metal Poisoning
1.3.4 Others
1.4 Asia-Pacific Antidote Market by Region
1.4.1 Asia-Pacific Antidote Market Size (Value) Comparison by Region (2014-2024)
1.4.2 China Status and Prospect (2014-2024)
1.4.3 Japan Status and Prospect (2014-2024)
1.4.4 South Korea Status and Prospect (2014-2024)
1.4.5 Taiwan Status and Prospect (2014-2024)
1.4.6 India Status and Prospect (2014-2024)
1.4.7 Southeast Asia Status and Prospect (2014-2024)
1.4.8 Australia Status and Prospect (2014-2024)
1.5 Asia-Pacific Market Size (Value and Volume) of Antidote (2014-2024)
1.5.1 Asia-Pacific Antidote Sales and Growth Rate (2014-2024)
1.5.2 Asia-Pacific Antidote Revenue and Growth Rate (2014-2024)
2 Asia-Pacific Antidote Competition by Players/Suppliers, Region, Type and Application
2.1 Asia-Pacific Antidote Market Competition by Players/Suppliers
2.1.1 Asia-Pacific Antidote Sales Volume and Market Share of Key Players/Suppliers (2014-2019)
2.1.2 Asia-Pacific Antidote Revenue and Share by Players/Suppliers (2014-2019)
2.2 Asia-Pacific Antidote (Volume and Value) by Type
2.2.1 Asia-Pacific Antidote Sales and Market Share by Type (2014-2019)
2.2.2 Asia-Pacific Antidote Revenue and Market Share by Type (2014-2019)
2.3 Asia-Pacific Antidote (Volume) by Application
2.4 Asia-Pacific Antidote (Volume and Value) by Region
2.4.1 Asia-Pacific Antidote Sales and Market Share by Region (2014-2019)
2.4.2 Asia-Pacific Antidote Revenue and Market Share by Region (2014-2019)
3 China Antidote (Volume, Value and Sales Price)
3.1 China Antidote Sales and Value (2014-2019)
3.1.1 China Antidote Sales Volume and Growth Rate (2014-2019)
3.1.2 China Antidote Revenue and Growth Rate (2014-2019)
3.1.3 China Antidote Sales Price Trend (2014-2019)
3.2 China Antidote Sales Volume and Market Share by Type
3.3 China Antidote Sales Volume and Market Share by Application
4 Japan Antidote (Volume, Value and Sales Price)
4.1 Japan Antidote Sales and Value (2014-2019)
4.1.1 Japan Antidote Sales Volume and Growth Rate (2014-2019)
4.1.2 Japan Antidote Revenue and Growth Rate (2014-2019)
4.1.3 Japan Antidote Sales Price Trend (2014-2019)
4.2 Japan Antidote Sales Volume and Market Share by Type
4.3 Japan Antidote Sales Volume and Market Share by Application
5 South Korea Antidote (Volume, Value and Sales Price)
5.1 South Korea Antidote Sales and Value (2014-2019)
5.1.1 South Korea Antidote Sales Volume and Growth Rate (2014-2019)
5.1.2 South Korea Antidote Revenue and Growth Rate (2014-2019)
5.1.3 South Korea Antidote Sales Price Trend (2014-2019)
5.2 South Korea Antidote Sales Volume and Market Share by Type
5.3 South Korea Antidote Sales Volume and Market Share by Application
6 Taiwan Antidote (Volume, Value and Sales Price)
6.1 Taiwan Antidote Sales and Value (2014-2019)
6.1.1 Taiwan Antidote Sales Volume and Growth Rate (2014-2019)
6.1.2 Taiwan Antidote Revenue and Growth Rate (2014-2019)
6.1.3 Taiwan Antidote Sales Price Trend (2014-2019)
6.2 Taiwan Antidote Sales Volume and Market Share by Type
6.3 Taiwan Antidote Sales Volume and Market Share by Application
7 India Antidote (Volume, Value and Sales Price)
7.1 India Antidote Sales and Value (2014-2019)
7.1.1 India Antidote Sales Volume and Growth Rate (2014-2019)
7.1.2 India Antidote Revenue and Growth Rate (2014-2019)
7.1.3 India Antidote Sales Price Trend (2014-2019)
7.2 India Antidote Sales Volume and Market Share by Type
7.3 India Antidote Sales Volume and Market Share by Application
8 Southeast Asia Antidote (Volume, Value and Sales Price)
8.1 Southeast Asia Antidote Sales and Value (2014-2019)
8.1.1 Southeast Asia Antidote Sales Volume and Growth Rate (2014-2019)
8.1.2 Southeast Asia Antidote Revenue and Growth Rate (2014-2019)
8.1.3 Southeast Asia Antidote Sales Price Trend (2014-2019)
8.2 Southeast Asia Antidote Sales Volume and Market Share by Type
8.3 Southeast Asia Antidote Sales Volume and Market Share by Application
9 Australia Antidote (Volume, Value and Sales Price)
9.1 Australia Antidote Sales and Value (2014-2019)
9.1.1 Australia Antidote Sales Volume and Growth Rate (2014-2019)
9.1.2 Australia Antidote Revenue and Growth Rate (2014-2019)
9.1.3 Australia Antidote Sales Price Trend (2014-2019)
9.2 Australia Antidote Sales Volume and Market Share by Type
9.3 Australia Antidote Sales Volume and Market Share by Application
10 Asia-Pacific Antidote Players/Suppliers Profiles and Sales Data
10.1 Boehringer Ingelheim
10.1.1 Company Basic Information, Manufacturing Base and Competitors
10.1.2 Antidote Product Category, Application and Specification
10.1.2.1 Product A
10.1.2.2 Product B
10.1.3 Boehringer Ingelheim Antidote Sales, Revenue, Price and Gross Margin (2014-2019)
10.1.4 Main Business/Business Overview
10.2 AstraZeneca
10.2.1 Company Basic Information, Manufacturing Base and Competitors
10.2.2 Antidote Product Category, Application and Specification
10.2.2.1 Product A
10.2.2.2 Product B
10.2.3 AstraZeneca Antidote Sales, Revenue, Price and Gross Margin (2014-2019)
10.2.4 Main Business/Business Overview
10.3 Novartis
10.3.1 Company Basic Information, Manufacturing Base and Competitors
10.3.2 Antidote Product Category, Application and Specification
10.3.2.1 Product A
10.3.2.2 Product B
10.3.3 Novartis Antidote Sales, Revenue, Price and Gross Margin (2014-2019)
10.3.4 Main Business/Business Overview
10.4 Eli Lilly
10.4.1 Company Basic Information, Manufacturing Base and Competitors
10.4.2 Antidote Product Category, Application and Specification
10.4.2.1 Product A
10.4.2.2 Product B
10.4.3 Eli Lilly Antidote Sales, Revenue, Price and Gross Margin (2014-2019)
10.4.4 Main Business/Business Overview
10.5 Portola
10.5.1 Company Basic Information, Manufacturing Base and Competitors
10.5.2 Antidote Product Category, Application and Specification
10.5.2.1 Product A
10.5.2.2 Product B
10.5.3 Portola Antidote Sales, Revenue, Price and Gross Margin (2014-2019)
10.5.4 Main Business/Business Overview
10.6 Pfizer
10.6.1 Company Basic Information, Manufacturing Base and Competitors
10.6.2 Antidote Product Category, Application and Specification
10.6.2.1 Product A
10.6.2.2 Product B
10.6.3 Pfizer Antidote Sales, Revenue, Price and Gross Margin (2014-2019)
10.6.4 Main Business/Business Overview
10.7 Bristol-Myers Squibb
10.7.1 Company Basic Information, Manufacturing Base and Competitors
10.7.2 Antidote Product Category, Application and Specification
10.7.2.1 Product A
10.7.2.2 Product B
10.7.3 Bristol-Myers Squibb Antidote Sales, Revenue, Price and Gross Margin (2014-2019)
10.7.4 Main Business/Business Overview
10.8 Bayer
10.8.1 Company Basic Information, Manufacturing Base and Competitors
10.8.2 Antidote Product Category, Application and Specification
10.8.2.1 Product A
10.8.2.2 Product B
10.8.3 Bayer Antidote Sales, Revenue, Price and Gross Margin (2014-2019)
10.8.4 Main Business/Business Overview
11 Antidote Manufacturing Cost Analysis
11.1 Antidote Key Raw Materials Analysis
11.1.1 Key Raw Materials
11.1.2 Price Trend of Key Raw Materials
11.1.3 Key Suppliers of Raw Materials
11.1.4 Market Concentration Rate of Raw Materials
11.2 Proportion of Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Manufacturing Process Analysis of Antidote
12 Industrial Chain, Sourcing Strategy and Downstream Buyers
12.1 Antidote Industrial Chain Analysis
12.2 Upstream Raw Materials Sourcing
12.3 Raw Materials Sources of Antidote Major Manufacturers in 2016
12.4 Downstream Buyers
13 Marketing Strategy Analysis, Distributors/Traders
13.1 Marketing Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.1.3 Marketing Channel Development Trend
13.2 Market Positioning
13.2.1 Pricing Strategy
13.2.2 Brand Strategy
13.2.3 Target Client
13.3 Distributors/Traders List
14 Market Effect Factors Analysis
14.1 Technology Progress/Risk
14.1.1 Substitutes Threat
14.1.2 Technology Progress in Related Industry
14.2 Consumer Needs/Customer Preference Change
14.3 Economic/Political Environmental Change
15 Asia-Pacific Antidote Market Forecast (2019-2024)
15.1 Asia-Pacific Antidote Sales Volume, Revenue and Price Forecast (2019-2024)
15.1.1 Asia-Pacific Antidote Sales Volume and Growth Rate Forecast (2019-2024)
15.1.2 Asia-Pacific Antidote Revenue and Growth Rate Forecast (2019-2024)
15.1.3 Asia-Pacific Antidote Price and Trend Forecast (2019-2024)
15.2 Asia-Pacific Antidote Sales Volume, Revenue and Growth Rate Forecast by Region (2019-2024)
15.2.1 Asia-Pacific Antidote Sales Volume and Growth Rate Forecast by Region (2019-2024)
15.2.2 Asia-Pacific Antidote Revenue and Growth Rate Forecast by Region (2019-2024)
15.2.3 China Antidote Sales, Revenue and Growth Rate Forecast (2019-2024)
15.2.4 Japan Antidote Sales, Revenue and Growth Rate Forecast (2019-2024)
15.2.5 South Korea Antidote Sales, Revenue and Growth Rate Forecast (2019-2024)
15.2.6 Taiwan Antidote Sales, Revenue and Growth Rate Forecast (2019-2024)
15.2.7 India Antidote Sales, Revenue and Growth Rate Forecast (2019-2024)
15.2.8 Southeast Asia Antidote Sales, Revenue and Growth Rate Forecast (2019-2024)
15.2.9 Australia Antidote Sales, Revenue and Growth Rate Forecast (2019-2024)
15.3 Asia-Pacific Antidote Sales, Revenue and Price Forecast by Type (2019-2024)
15.3.1 Asia-Pacific Antidote Sales Forecast by Type (2019-2024)
15.3.2 Asia-Pacific Antidote Revenue Forecast by Type (2019-2024)
15.3.3 Asia-Pacific Antidote Price Forecast by Type (2019-2024)
15.4 Asia-Pacific Antidote Sales Forecast by Application (2019-2024)
16 Research Findings and Conclusion
17 Appendix
17.1 Methodology/Research Approach
17.1.1 Research Programs/Design
17.1.2 Market Size Estimation
17.1.3 Market Breakdown and Data Triangulation
17.2 Data Source
17.2.1 Secondary Sources
17.2.2 Primary Sources
17.3 Disclaimer
Request Discount 
Inquire Before Buy
